OBJECTIVES Neuroblastoma (NB) is a rare cancer of childhood, with nearly 90% of cases diagnosed by age 5 (ACS 2013).  Our objective was to report the utilisation and cost of hospital services related to patients who have a diagnosis of NB and High Risk NB (HRNB) reported in an England dataset from a Clinical Commissioning Group (CCG) perspective. METHODS We used an England dataset covering hospital events (April 2010 - September 2013).  Patients were included if they were under age 18 and had a hospital event with a primary or secondary diagnosis coded as International Classification of Disease 10^thEdition (ICD10) C749.  Newly diagnosed patients were identified if they had no hospital events in the first 4 months of the study period.  From this newly diagnosed cohort we identified a HRNB cohort (bone marrow transplant) that included patients who had a high risk procedure that did not occur in the last 12 months of the study period.  Cost and utilisation is reported from hospital admissions, emergency department visits, and outpatient attendances.  RESULTS We observed 336 patients as newly diagnosed and an additional 33 patients were identified as HRNB.  Newly diagnosed population inpatient admits were 12 per patient, compared with 22 per patient for the HRNB population.  Total costs associated with the 336 newly diagnosed patients were £24.3m.  Total costs associated with the 33 HRNB patients were £4.3m.  Costs per HRNB patient (£130,303) were almost double the costs per newly diagnosed patient (£72,321).  The average length of stay was 6 days for both sets of patients. CONCLUSIONS To our knowledge this is the first retrospective analysis of NB cost and utilisation using encounter data from England.  While it does not capture the entire costs to the England healthcare system, it indicates the level of resource intensity and cost at the CCG level.